

Amgen Quick Facts:

Headquarters

Thousand Oaks, California

Staff

Approximately 24,000 worldwide

Stock Listing

NASDAQ: AMGN

Chairman and CEO

Robert A. Bradway

2021 Financial Highlights

Total revenue: \$26.0 billion

Product sales: \$24.3 billion

R&D expense: \$4.8 billion

Address/Phone

One Amgen Center Drive

Thousand Oaks, CA 91320-1799

Main: (805) 447-1000

Investors: (805) 447-1060

PRODUCTS

Aimovig® (erenumab-aooe)

AMGEVITA™ (adalimumab)

Aranesp® (darbepoetin alfa)

AVSOLA™ (infliximab-axxq)

BLINCYTO® (blinatumomab)

Corlanor® (ivabradine)

Enbrel® (etanercept)

EPOGEN® (epoetin alfa)

EVENITY® (romosozumab-aqqg)

IMLYGIC® (talimogene laherparepvec)

KANJINTI™ (trastuzumab-anns)

KYPROLIS® (carfilzomib)

LUMAKRAS™ (sotorasib)

MVASI™ (bevacizumab-awwb)

Neulasta® (pegfilgrastim)

NEUPOGEN® (filgrastim)

Nplate® (romiplostim)

Otezla® (apremilast)

Parsabiv® (etelcalcetide)

Prolia® (denosumab)

Repatha® (evolocumab)

RIABNI™ (rituximab-arrx)

Sensipar®/Mimpara® (cinacalcet)

TEZSPIRE™ (tezepelumab-ekko)

Vectibix® (panitumumab)

XGEVA® (denosumab)

Aimovig® is developed in collaboration with Novartis. For information about our pipeline and therapies, visit www.amgen.com.

About Amgen

Our Mission: To Serve Patients

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

INNOVATIVE MEDICINES

We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

TRANSFORMATIVE RESEARCH

Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

WORLD-CLASS BIOMANUFACTURING

The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.

OUR HERITAGE

Building on advances in recombinant DNA and molecular biology, Amgen is counted among the early pioneers of biotechnology. Since 1980, Amgen scientists have been at work developing novel therapies for patients with serious illnesses. Our scientists have characterized key biologic processes that have led to the development of innovative, first-in-class therapies. We have helped shape the scientific world's understanding of certain disease processes, and we have engineered new types of therapeutic platforms. As a company, we could not have accomplished what we have were it not for our deep commitment to building a culture that embraces science and innovation—a culture that continues to shape who we are today.

THE AMGEN FOUNDATION

The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated nearly \$300 million in grants to local, regional and international nonprofit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars, Amgen Biotech Experience and Amgen Teach. For more information, visit www.AmgenInspires.com.

REACHING PATIENTS WORLDWIDE

Amgen medicines help patients worldwide with facilities or subsidiaries in the following locations:

In the United States

California (South San Francisco, Thousand Oaks)
Florida (Tampa)
Kentucky (Louisville)
Massachusetts (Cambridge, Woburn)
Puerto Rico (Juncos)
Rhode Island (West Greenwich)
Washington, D.C.

Outside the United States

Algeria	Estonia	Korea	Saudi Arabia
Argentina	Finland	Latvia	Singapore
Australia	France	Lebanon	Slovakia
Austria	Germany	Lithuania	Slovenia
Belgium	Greece	Luxembourg	South Africa
Brazil	Hong Kong	Mexico	Spain
Bulgaria	Hungary	Morocco	Sweden
Canada	Iceland	Netherlands	Switzerland
China	India	New Zealand	Taiwan
Colombia	Ireland	Norway	Thailand
Croatia	Israel	Poland	Turkey
Czech Republic	Italy	Portugal	United Arab Emirates
Denmark	Japan	Romania	United Kingdom
Egypt	Jordan	Russia	

Investor Information

This fact sheet is a summary of more detailed disclosure that can be found in Amgen's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Amgen's most recent Forms 10-K, 10-Q, and 8-K and on

<http://investors.amgen.com>. The information in this fact sheet is given as of the date below, and Amgen does not undertake any obligation to update any information in this document.



SENIOR MANAGEMENT

[Robert A. Bradway](#)
Chairman and Chief Executive Officer

[Victoria H. Blatter](#)
SVP, Global Government Affairs and Policy

[Judy Gawlik Brown](#)
SVP, Corporate Affairs

[Raymond Deshaies](#)
SVP, Global Research

[Jackie Elbonne](#)
SVP, Quality and Chief Quality Officer

[Murdo Gordon](#)
EVP, Global Commercial Operations

[Jonathan Graham](#)
EVP, General Counsel and Secretary

[Peter Griffith](#)
EVP and Chief Financial Officer

[Nancy Grygiel](#)
SVP, Worldwide Compliance & Business Ethics and Chief Compliance Officer

[Lori Johnston](#)
EVP

[My Linh Kha](#)
SVP, General Manager Japan Asia-Pacific

[Rachna Khosla](#)
SVP, Business Development

[Robert Lenz](#)
SVP, Global Development

[Gilles Marrache](#)
SVP, Regional General Manager

[Derek Miller](#)
SVP, Human Resources

[Jerry Murry](#)
SVP, Process Development

[Arleen Paulino](#)
SVP, Manufacturing

[Annalisa Pizzarello](#)
SVP, Results Delivery Office

[Anton Rabushka](#)
SVP, Finance

[David M. Reese](#)
EVP, Research and Development

[Esteban Santos](#)
EVP, Operations

[Darryl Sleep](#)
SVP, Global Medical and Chief Medical Officer

[Jean-Charles Soria](#)
SVP, Research and Development

[Susan Sweeney](#)
SVP, Global Marketing, Access and Capabilities

[Mark Taisey](#)
SVP, Global Regulatory Affairs and Strategy

[Ian Thompson](#)
SVP, U.S. Business Operations

[Michael Zahigian](#)
SVP, Chief Information Officer